SkyView Investment Advisors LLC Cuts Position in Liquidia Co. (NASDAQ:LQDA)

SkyView Investment Advisors LLC lowered its holdings in Liquidia Co. (NASDAQ:LQDA) by 27.5% in the third quarter, Holdings Channel.com reports. The fund owned 50,000 shares of the company’s stock after selling 18,999 shares during the quarter. SkyView Investment Advisors LLC’s holdings in Liquidia were worth $500,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Whitcomb & Hess Inc. lifted its stake in shares of Liquidia by 10.2% in the third quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock valued at $116,000 after purchasing an additional 1,074 shares during the period. Arizona State Retirement System lifted its position in shares of Liquidia by 10.7% during the 2nd quarter. Arizona State Retirement System now owns 13,842 shares of the company’s stock valued at $166,000 after acquiring an additional 1,341 shares during the period. Quest Partners LLC purchased a new stake in shares of Liquidia during the 2nd quarter worth approximately $27,000. Price T Rowe Associates Inc. MD increased its stake in Liquidia by 26.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,341 shares of the company’s stock valued at $212,000 after purchasing an additional 2,999 shares in the last quarter. Finally, Profund Advisors LLC increased its stake in Liquidia by 31.6% in the 2nd quarter. Profund Advisors LLC now owns 14,434 shares of the company’s stock valued at $173,000 after purchasing an additional 3,466 shares in the last quarter. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Rajeev Saggar sold 2,260 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $25,108.60. Following the sale, the insider now directly owns 207,383 shares of the company’s stock, valued at approximately $2,304,025.13. This trade represents a 1.08 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Russell Schundler sold 2,576 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $28,619.36. Following the transaction, the general counsel now directly owns 486,048 shares of the company’s stock, valued at $5,399,993.28. This trade represents a 0.53 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,007 shares of company stock valued at $245,780 over the last quarter. Company insiders own 30.10% of the company’s stock.

Liquidia Stock Performance

Shares of NASDAQ LQDA opened at $11.01 on Friday. The firm’s 50 day moving average price is $10.91 and its 200 day moving average price is $11.26. Liquidia Co. has a 1 year low of $6.90 and a 1 year high of $16.99.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Lifesci Capital initiated coverage on Liquidia in a report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price on the stock. Raymond James raised shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a research note on Monday, August 19th. BTIG Research cut their target price on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, August 19th. Bank of America lowered their price target on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. Finally, Needham & Company LLC restated a “buy” rating and set a $19.00 price objective on shares of Liquidia in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $24.00.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).